The US Food and Drug Administration (FDA) has finalized guidance specifying that after 1 April 2026, sponsors will have to submit investigational new drug (IND) safety reports for serious and ...
FDA Offers Draft Guidance on IND Safety Reporting For investigational new drug application (IND) sponsors running clinical trials and debating when a serious adverse event can be linked to an ...
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results